Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Voyager Therapeut (NQ: VYGR )

7.000 +0.170 (+2.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Voyager Therapeut

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
In-Depth Examination Of 4 Analyst Recommendations For Voyager Therapeutics
Via Benzinga
Get “Picky” With Stocks For September Profits
Via Talk Markets
3 High-Growth Stocks Poised To Double By Next Year
The article outlines three high-growth stocks that could double by 2025, using specific screening criteria: strong buy ratings from multiple analysts, significant revenue and earnings growth, and... 
Via Talk Markets
7 Biotech Stocks to Buy for Their Game-Changing Potential
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
What Analysts Are Saying About Voyager Therapeutics Stock
Via Benzinga
Is VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) suited for growth investing?
Should you consider VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) for growth investing? 
Via Chartmill
Is NASDAQ:VYGR a Fit for Growth Investing Strategies?
High growth, ROE and relative strength for VOYAGER THERAPEUTICS INC (NASDAQ:VYGR), growth investors may appreciate this. 
Via Chartmill
VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q2 2024
VYGR stock results show that Voyager Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024
VYGR stock results show that Voyager Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider. 
Via InvestorPlace
Delving into NASDAQ:VYGR's Growth Prospects.
Why VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) qualifies as a high growth stock. 
Via Chartmill
Cheap Thrills: 7 Promising Value Stocks You Can Buy for Under $20
With so many thousands of securities available, there are bound to be compelling ideas for value stocks under $20. 
Via InvestorPlace
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term... 
Via Benzinga
Exploring NASDAQ:VYGR's growth characteristics.
VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Is VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) suited for growth investing?
Unlocking the Growth Potential of VOYAGER THERAPEUTICS INC (NASDAQ:VYGR). 
Via Chartmill
Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge
Tech stocks drive pre-market surge, Fed inflation data fails to disrupt rate cut expectations. Futures up for Nasdaq, S&P 500, and small caps. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Okta Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket
Shares of Okta, Inc. (NASDAQ: OKTA) shares rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and 
Via Benzinga
Voyager Therapeutics: Q4 Earnings Insights
Via Benzinga
Earnings Preview For Voyager Therapeutics
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the news affecting shares this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
Financial Frontrunners: 3 Stocks Where the Big Money Is Moving in 2024
The 2024 investment trends are slowly making themselves known. Make sure you follow our guide to stay ahead of the curb. 
Via InvestorPlace
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Voyager Therapeutics stock pops 30% on deal with Novartis
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took 
Via MarketBeat
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Applied Therapeutics, Inc. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.